RxDoctor Payments Data

Demetrio Roland Flores, MD

Interventional Cardiology · Salem, MANPI 1588976922

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 34 payments — averaging $33.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$375
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$218
  • Shockwave Medical, Inc$172
  • Edwards Lifesciences$121
  • AstraZeneca$80
  • Pfizer$61
  • plus $97 from 3 others

What the payments were for

  • Food & beverage$1,04593%
  • Education$807%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 25th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$168,577
Medicare patients
1,115
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$51,259
XareltoRivaroxaban15$21,633
JardianceEmpagliflozin18$20,026
Metoprolol Succinate100$1,510
Ezetimibe39$1,459
Atorvastatin Calcium98$1,268
Isosorbide Mononitrate ErIsosorbide Mononitrate33$576
Torsemide13$474
Nitroglycerin20$440
Lisinopril33$407
Amlodipine Besylate40$276
ClopidogrelClopidogrel Bisulfate24$239
Furosemide34$180
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$176
Losartan Potassium24$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$61$51,25937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 128 interventional cardiology providers in Massachusetts.

Other interventional cardiology in Salem

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →